AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Atrium Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG01Z0T3B63
8.20▲ 0.04 (0.49%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
—
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
8.16
Day's Range
7.78 – 8.21
52-Week Range
7.49 – 73.06
Volume
192.6K
Avg Volume
299.1K
Share Statistics
Shares Outstanding
Employees
391
Exchange
XNAS
Listed
2026-02-27
Share count as of August 3, 2026

Atrium Therapeutics, Inc. Common Stock (RNA) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Atrium Therapeutics, Inc. Common Stock (RNA)
What is Atrium Therapeutics, Inc. Common Stock's Market Cap?
Atrium Therapeutics, Inc. Common Stock's Market Cap is $140.3M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · RNAAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Jun 30, 2025Mar 31, 2025
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue852.9%188.0%
Loss from operations
% of revenue-752.9%-88.0%
Other income (expense)
Interest income—
Other income (expense), net—
Total other income (expense)
Net loss
% of revenue-672.0%-84.7%
Basic net loss per common share
Diluted net loss per common share